Peter Clark, MD, professor of medicine and chair of urology, Levine Cancer Institute, Atrium Health, discusses the need for biomarkers in renal cell carcinoma.
Peter Clark, MD
Advertisement
Articles by Peter Clark, MD
Peter Clark, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma (RCC).
Peter Clark, MD, medical oncologist, Levine Cancer Institute, discusses the potential of immunotherapy in the treatment of patients with renal cell carcinoma (RCC).
Advertisement
Latest Updated Articles
Dr. Clark on the Potential of Immunotherapy in Renal Cell CarcinomaPublished: October 26th 2018 | Updated:
Dr. Clark on the Role of Cytoreductive Nephrectomy in RCCPublished: November 27th 2018 | Updated:
Dr. Clark Discusses Need for Biomarkers in RCCPublished: January 24th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5